Eradivir Begins Phase 2 Challenge Trial for Antiviral Therapeutic EV25

Eradivir Begins Phase 2 Challenge Trial for Antiviral Therapeutic EV25

Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has initiated a Phase 2 challenge trial of its antiviral therapeutic EV25. The study provides safety and effectiveness data collected from otherwise healthy participants who were infected with influenza and later treated with EV25.

EV25 was built on a platform created in Philip Low's laboratory. Low is the Presidential Scientist in Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in Purdue University's College of Science. Low is Eradivir's chief scientific officer and on the board of directors.

The European Medicines Agency and Belgium's Federal Agency for Medicines and Health Products approved the Phase 2 challenge study following successful completion of a Phase 1 study of EV25. Based on the Phase 1 preliminary safety results, a safety review committee including study staff and independent physicians concluded that the compound was well tolerated by participants.

Eradivir CEO Martin Low said the company was moving quickly into the challenge trial because of its confidence in EV25.

We have conducted over 150 preclinical studies with EV25, which demonstrated the ability to quickly clear the virus in the lungs, even when taken 96 hours after infection. These studies have also demonstrated EV25's ability to treat multiple flu strains, including pandemic strains and those resistant to current flu drugs. We were able to positively differentiate EV25 across several other parameters from currently available therapies. Our preclinical research was recently published in the peer-reviewed Nature Communications and Proceedings of the National Academy of Sciences. “

Martin Low, CEO of Eradivir

The Phase 2 Challenge study will test up to 60 people, providing preliminary data on the effectiveness of EV25 against influenza and confirming its safety. Data from the Phase 1 and Phase 2 Challenge trials will be available in September.

Given the Challenge study results, a Phase 2B patient study will begin in the U.S. and Europe this fall at the start of the 2025-26 flu season. This larger study includes approximately 375 participants.

Purdue connections

Philip Low is on the faculty of the Purdue Institute for Drug Discovery and the Purdue Institute for Cancer Research. Low's research supports Purdue's unique health mission, which promotes innovation at the intersection of human, animal and plant health.

Eradivir is a Purdue Strategic Ventures Portfolio Company.

Sources: